All posts by medical

RAPT Therapeutics Announces Upcoming Investor Conference Presentations – Yahoo Finance

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., its President and CEO, will be presenting at two upcoming conferences:

A live webcast and audio archive of both presentations may be accessed on the RAPT Therapeutics website athttps://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

AboutRAPT Therapeutics, Inc.RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including general control nonderepressible 2 (GCN2) and hematopoietic progenitor kinase 1 (HPK1), that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

Read the original here:
RAPT Therapeutics Announces Upcoming Investor Conference Presentations - Yahoo Finance

Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA | More News | News Channels -…

DetailsCategory: More NewsPublished on Thursday, 20 February 2020 13:06Hits: 227

BERKELEY, CA & RICHMOND, CA, USA I February 19, 2020 I Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies. Caribou intends to utilize this scFv in the development of its CB-011 program, an allogeneic CAR-T therapy targeting BCMA-positive tumors including multiple myeloma.

We are excited for the opportunity to have access to this highly advanced, humanized molecule and believe it will significantly advance our promising CB-011 CAR-T program, said Steven Kanner, PhD, Chief Scientific Officer of Caribou.

We anticipate that our humanized BCMA scFv will aid greatly in Caribous efforts to further its allogeneic CAR-T program, and hope our technology continues to improve the field of preclinical and clinical stage immunotherapy research by providing broad choices of validated antibodies, said John Wu, MD, Chief Executive Officer of ProMab.

Under the terms of the agreement, ProMab received an upfront payment and is eligible for royalties on net sales of licensed products containing the BCMA scFv.

About Caribou Biosciences, Inc. Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes. Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at This email address is being protected from spambots. You need JavaScript enabled to view it.. For more information about Caribou, visit http://www.cariboubio.com and follow the Company @CaribouBio. Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

About ProMab Biotechnologies, Inc. ProMab Biotechnologies focuses on developing and commercializing mouse, rabbit, and human monoclonal antibodies as well as chimeric antigen receptor-T Cell (CAR-T) products. ProMabs CAR-T platform covers both hematological and solid cancers with intensive in vitro and in vivo pre-clinical validation designed for safer and better treatment. As a CRO in the immunology field for 19 years, ProMab offers standard laboratory procedures and animal studies for antibody discovery through the integration of the newest techniques in antibody library construction, next generation sequencing, unique humanization modeling, high-throughput screening, and artificial intelligence analysis systems. ProMab aims to out-license antibodies validated in CAR-T therapy in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study. ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of cell therapies as well as bispecific antibodies targeting multiple cancers. For more information, visit http://www.promab.com.

SOURCE: Caribou Biosciences

Read more here:
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA | More News | News Channels -...

Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit -…

Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models

CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that the companys therapeutic Immuno-STAT (Selective Targeting and Alteration of T cells) platform is scheduled to be featured in a Merck presentation at the Antigen-Specific Immune Tolerance Drug Development Summit taking place on Feb. 25-27, 2020 at the Colonnade Hotel in Boston, Massachusetts. Cue entered into a strategic research collaboration and license agreement with Merck in November 2017 to develop biologics for the treatment of selected autoimmune diseases.

Presentation DetailsTitle: Antigen Specific Immunotherapy Approaches for the Treatment of Autoimmune Diseases Presenter: Emilio Flano, Executive Director and Head of Immunology Discovery, Merck & Co., Inc.Date & Time:Feb. 26 at 8:00 a.m. ET

This presentation demonstrates the modularity of the Immuno-STAT platform and its potential for addressing the pressing unmet need for treating autoimmune disease through the selective down modulation of self-reactive T cells associated with autoimmune disorders, said Anish Suri, Ph.D., president and chief scientific officer ofCue Biopharma.An Immuno-STAT has been made to selectively deliver a PD-L1 inhibitory signal to CD4 T cells reactive to the proinsulin protein, which is associated with type 1 diabetes.This Immuno-STAT selectively inhibited the expansion of proinsulin reactive T cells isolated from the blood of type 1 diabetes patients, and also selectively inhibited the functional response of proinsulin-specific CD4 T cells when the Immuno-STAT was administered to transgenic mice.

About Immuno-STATImmuno-STAT biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-regulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patients body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients T cells to be extracted, modified outside the body (ex vivo), and reinfused.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The companys proprietary Immuno-STAT(Selective Targeting and Alteration of T cells) platformis designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered inCambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology treatments.

For more information, visitwww.cuebio.com and follow us on Twitter https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe,

expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; our ability to secure requiredU.S. Food and Drug Administration(FDA) or other governmental approvals for our product candidates and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to theFDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact

Ashley R. RobinsonLifeSci Advisorsarr@lifesciadvisors.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com

Read more:
Cue Biopharma's Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit -...

CAA to vote on revision to credit for prior learning – The Daily Eastern News

The Council on Academic Affairs will vote on an action item to revise credit for prior learning during its meeting Thursday at 2 p.m. in Room 4440 of Booth Library.

If approved, the proposal will change the language for the credit for prior learning via portfolio section of the catalog.

The change will delete most of the language and add in some leaving the policy to say: Eastern Illinois University awards credit for prior learning following the Council for Adult and Experiential Learning (CAEL) standards. Students should consult their major department to determine if the program they are enrolled in accepts course credit earned through prior learning via portfolio, and to obtain information about all relevant procedures and protocol.

In the rationale for the changes it says the change is necessary because the potential new language creates general language that can be applied to any and all academic programs, thus reducing potential future edits to the governing academic regulations.

The council will also vote on a new biochemistry minor.

Currently there is a biochemistry major but not a complimentary minor for it available with chemistry majors and minors.

The rationale for the proposed new minor is to reward students who are not biochemistry majors but have taken additional courses with a biochemistry major and the new minor will be of interest to students in other degree programs who are seeking to enter the life sciences job sector or interdisciplinary graduate programs.

CAA will vote on revisions to the management information systems major and hospitality and tourism management option.

The council will also vote on revisions to the neuroscience and religious studies.

CAA will also vote on:

A new course, Introduction to Databases for Business Analytics

A new course, Introduction to Business Intelligence

A new course, Business Analytics Project

A revised course, Business Analytics Programming

A revised course, Economic Botany

The council will discuss suspension of its bylaws and revising the nomination requirements for faculty laureate.

Corryn Brock can be reached at 581-2812 or at [emailprotected].

See the original post:
CAA to vote on revision to credit for prior learning - The Daily Eastern News

New teaching methods to serve a younger generation of students – The Hechinger Report

The Hechinger Report is a national nonprofit newsroom that reports on one topic: education. Sign up for our weekly newsletters to get stories like this delivered directly to your inbox.

The Hechinger Reportis collaborating withThe New York Timesto produce Bulletin Board, page 2 of theTimess education supplement, Learning.

Sydney Rosario modeling the concept of hydrogen bonding in fifth grade last year at Our Lady of Mercy Academy in Park Ridge, N.J. Photo: Gabriela Fuentes

Biochemistry can be elementary

Students generally learn about moles, atoms, compounds and the intricacies of the periodic table in college, but Daniel Fried is convinced kids can learn complex biochemistry topics as early as elementary school.

Fried is an assistant professor of chemistry at Saint Peters University in New Jersey, and in his spare time, he creates biochemistry lessons for kids, teaching fourth through sixth graders at a nearby Montessori school and sharing lessons with other teachers and homeschooling parents around the country and world.

When the kids are young, theyre highly motivated, Fried said. Its easy to teach them. They pick up on the patterns so quickly. They appreciate everything. High school and college students, by contrast, take a lot more work to engage and tend to want to learn only what they need to pass a test, he said.

Fried has found getting children interested in biochemistry to be a breeze especially when they hear theyll soon be able to correct older siblings or cousins. The harder part is getting the adults on board to allow it to happen, he said.

At Hopatcong Middle School in northern New Jersey, Jim McKowen is one of the first public-school teachers to take on this curriculum. He teaches it to sixth graders. McKowen said after one lesson where students learn about flavor molecules, kids go home and scour ingredient labels for chemicals they recognize. After his class, he said, kids doodle molecules in their school notebooks.

Fried has introduced biochemistry to students of various ethnic groups and socioeconomic statuses in schools and museums, finding that all of them happily grapple with the curriculum. While men tend to dominate STEM fields, girls are as interested in these lessons as boys, he said.

Both teachers think the curriculum could bring more diversity to STEM. Hopefully it does translate into a greater interest in science later in life and we start to see those results, McKowen said.

To get there, though, teachers have to believe children are capable of more than they may think.

We do sell kids short sometimes, McKowen said. TARA GARCA MATHEWSON

Fake frogs; real lessons

Dissection day always made Karina Frey queasy. Even as a self-proclaimed science and math girl, she didnt like the idea of cutting into an animals chemically-preserved body.

I believe that animals have souls too, said Karina, a senior at J.W. Mitchell High School in New Port Richey, Florida.

With vegetarianism and environmental concerns on the rise among young people, the option of learning on something that didnt have to die for that purpose is increasingly attractive.

The SynFrog is an alternative to the formaldehyde-preserved frogs currently used for dissection in schools nationwide. Photo: Judge Public Relations

Enter SynFrog: an amphibian thats as slimy as a real frog but never drew a breath.

The anatomically accurate fake frog made its debut at Karinas high school last November. It met with avid approval from biology teachers and students, according to Principal Jessica Schultz. She said the school usually goes through about 300 frogs a year, and several students in each class always opt out of the assignment.

Three million frogs are harvested each year for classroom dissections in the United States, according to People for the Ethical Treatment of Animals, which partnered with the manufacturing company SynDaver to develop the synthetic frog.

At $150, the first SynFrog was more expensive than a frog carcass ($7 to $10 each); the company hopes to reduce the price in the next version. As the frog is reusable for most dissections, the cost could be recuperated over time.

Since the frogs debut, the company has had trouble filling orders fast enough, according to its CEO and founder, Dr. Christopher Sakezles. If SynFrog catches on, it could change a staple of high school education. MEREDITH KOLODNER

A work college makes room for growth

With the average cost of college now about $20,000 annually at public and $41,000 at private institutions, many students have jobs to help cover costs. But at nine institutions federally designated as work colleges, working is incorporated into the curriculum to offset tuition and fees. Paul Quinn College, a historically black college in Dallas, became the newest work college in 2017, and the only urban one. Now it is expanding.

Were not one of those schools thats overstaffed, said Michael Sorrell, the colleges president. A lot of the jobs that other schools might hire people to do, weve invested in the students to do.

Classes are primarily held Monday, Wednesday and Friday, leaving Tuesday and Thursday for students to work uninterrupted. They work in the presidents office, on the campus farm (where you can find radishes, arugula, spinach, kohlrabi and more) and off campus at businesses such as JP Morgan Chase and Liberty Mutual.

The model clearly works well for Paul Quinn. The retention rate for first-year, full-time students rose from 63 percent before the change to 71 percent in the 2017-2018 year. Two new buildings are slated to open this summer one a residence hall, so enrollment can grow beyond the roughly 500 students it has now; the other a gym and wellness center with classroom space. And, having added a new campus in nearby Plano in 2018, school leaders are searching for the next site.

I think youll see another campus within the next three years, Sorrell said. DELECE SMITH-BARROW

Flexible design pushes desks aside

School desks neatly lined up in rows may soon be a relic of the past. Districts across the country are pouring millions into redesigning classrooms, trading the traditional layout for beanbags, rocking chairs and furniture on wheels. The North American school furniture market is expected to grow to $2.4 billion by 2024 from $1.7 billion in 2018 as technology-driven change increases the demand for more flexible classroom space.

Bryan Ballegeer of KI, a Wisconsin-based school furniture company, says this is what he hears from school administrators: Weve been sitting in the same chairs for 40 years and our school system is changing. We dont want any one part of the room to be the front of the room. We want our kids to collaborate more.

In response, KI eliminated some of its desk/chair combos. Its catalogue now includes standing or counter-height tables where students can work in teams and comfy couches where they can settle in to read.

To figure out if its furniture helps schools, KI completely re-outfitted some classrooms in nine schools and gave a before-and-after survey to students and teachers. Both groups reported higher levels of engagement and participation after the furniture swap. Other research backs up the idea that changing a classrooms physical characteristics can change what happens in it and improve student performance.

Still, Ballegeer, a former educator, offers a cautionary note. My advice is take a moment, talk with your teachers, talk with your community, he said. Its a big expense. SARAH BUTRYMOWICZ

How much do students really like tech?

Kids like technology. They like playing games, watching videos, finding music and interacting with their peers on social media. They like exploring the endless resources of the internet.

Educators notice this and assume its a safe bet that computers and other devices will capture students interest in school. Indeed, 93 percent of principals and 86 percent of teachers say that increased student engagement is the most important benefit of using computers and tablets in classrooms, according to the latest data from the Speak Up Research Initiative, which surveyed more than 26,000 teachers and librarians and almost 2,200 administrators last year. Nearly 70 percent of district administrators said they considered engagement to be the most effective sign that a piece of educational technology is useful.

Speak Up got a very different response from the roughly 290,000 students they surveyed: Just 41 percent of middle schoolers and 35 percent of high schoolers said they strongly associated classroom technology with increased engagement.

Whats more, anecdotal interviews, along with data from YouthTruth, a national nonprofit that conducts student surveys, indicate that many students actually dislike when teachers turn over instruction to computers. They say they prefer learning directly from teachers because they think teachers are the experts or that its their job and many complain about spending too much time on screens, between their schoolwork and their use of technology at home.

Gen Z may walk through life glued to smartphones. But that doesnt mean they want to use computers in class. TARA GARCA MATHEWSON

This story about new teaching methods was produced byThe Hechinger Report, a national nonprofit newsroom that reports on one topic: education. Sign up forour weekly newslettersto get stories like this delivered directly to your inbox.

Join us today.

Link:
New teaching methods to serve a younger generation of students - The Hechinger Report

Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood – Associated Press

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Click to copy

REHOVOT, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs). The specific claims being granted cover the use of Fourier Transformed Infrared Analysis (FTIR) spectroscopy and using artificial intelligence on the infrared (IR) data obtained to build algorithms based on the IR spectrum that are predictive of the presence of different types of solid tumors with different tissues of origin. The Company expects the patent to be issued in the coming weeks.

We are very pleased to see the expansion of the Todos intellectual property portfolio in Europe where Todos is currently in the midst of a pre-commercialization study with partner Orot+ (a division of Orot Luces) for our TM-B1 and TM-B2 breast cancer blood tests, said Gerald E. Commissiong, President & CEO of Todos Medical. This particular patent is very significant because it covers the method of using TBIA for the identification of solid tumors. The potential of this technology to eventually be used as a broad screening tool for all cancers, given the low costs of goods sold (COGS) to implement the assay, would represent a sea-change in terms of the ability to do broad cancer screenings for health systems.

About Todos Medical Ltd.Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimers disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancers influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The companys two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test, a blood test for diagnosing Alzheimers disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa breast cancer blood test.

For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com

Forward-looking StatementsCertain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Investor and Corporate Contact:Kim Sutton GolodetzLHA Investor RelationsSenior Vice President (212) 838-3777kgolodetz@lhai.com

Corporate ContactDaniel HirschTodos MedicalInvestor RelationsEmail: Dan.h@todosmedical.com Phone: (347) 699-0029

Read the original post:
Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood - Associated Press

Researchers get insights into functioning of mitochondria – The Siasat Daily

Washington D.C.: The inner membranes of mitochondria, called the powerhouse of cells, are not static as assumed earlier, but rather they constantly change their structure every few seconds in living cells, new research has found. This dynamic adaptation process further increases the performance of our cellular power plants.

Mitochondria are known as the powerhouse of the cell in plants, fungi and animals and until now it has been assumed that these functions underlie a static structure of mitochondrial membranes.

Researchers at the Heinrich Heine University Dusseldorf (HHU) and the University of California Los Angeles (UCLA), supported also by the Center for Advanced Imaging (CAi) of HHU, and In our opinion, this finding fundamentally changes the way our cellular power plants work and will probably change the textbooks, says Prof. Dr Andreas Reichert, Institute of Biochemistry and Molecular Biology I at the HHU. The results are described in a publication in EMBO Reports.

Mitochondria are extremely important components in cells performing vital functions including the regulated conversion of energy from food into chemical energy in the form of ATP. ATP is the energy currency of cells and an adult human being produces (and consumes) approximately 75 kilograms of ATP per day.

One molecule of ATP is produced about 20,000 times a day and then consumed again for energy utilization. This immense synthesis capacity takes place in the inner membrane of the mitochondria, which has numerous folds called cristae.

It was previously assumed that a specific static structure of the cristae ensured the synthesis of ATP. Whether and to what extent cristae membranes are able to dynamically adapt or alter their structure in living cells and which proteins are required to do so, was unknown.

The research team of Prof. Dr Andreas Reichert with Dr Arun Kondadi and Dr Ruchika Anand from the Institute of Biochemistry and Molecular Biology I of the HHU in collaboration with the research team of Prof. Dr Orian Shirihai and Prof. Dr Marc Liesa from UCLA (USA) succeeded for the first time in showing that cristae membranes in living cells continuously change their structure dynamically within seconds within mitochondria.

This showed that the cristae membrane dynamics requires a recently identified protein complex, the MICOS complex. Malfunctions of the MICOS complex can lead to various serious diseases, such as Parkinsons disease and a form of mitochondrial encephalopathy with liver damage. After the identification of the first protein component of this complex (Fcj1/Mic60) about ten years ago by Prof. Andreas Reichert and his research group, this is another important step to elucidate the function of the MICOS complex.

Our now published observations lead to the model that cristae, after membrane fission, can exist for a short time as isolated vesicles within mitochondria and then re-fuse with the inner membrane. This enables an optimal and extremely rapid adaptation to the energetic requirements in a cell, said Prof. Andreas Reichert.

Go here to read the rest:
Researchers get insights into functioning of mitochondria - The Siasat Daily

Faculty Feature: Darryl Aucoin: A SCIENCE PROFESSOR’S FORMULA FOR SUCCESS: TEAMWORK, HUMOR AND THE GREAT OUTDOORS – Caldwell University News

DARRYL AUCOIN:ASCIENCE PROFESSORSFORMULA FORSUCCESS:TEAMWORK, HUMORAND THEGREAT OUTDOORS

Professor Darryl Aucoin was describing the odd shape of a molecule to his chemistry students. Did you ever have your umbrella flip inside out? he asked. It kind of looks like that.

To explain how atoms and electrons relate, he showed his students a cartoon with a greatSnidley-Whiplash-looking chlorine atom (referring to an old TV villain) that was practically stealing an electron from a poor hydrogen, who is very distressed looking, said Aucoin, assistant professorin the Department of Natural Sciences.The team has the same primary goal in mind: It is laser-focused on the students That they know we really care, that we are there. All in it together.CL

Aucoin uses analogies to insert humor into the classroom when he is teaching a complicated subject. Most times his creative gymnastics come on the spur of the moment. I often find that I come up with them in the middle of the lectureand I cant remember them later when I try to write them down, he said. The comparisons relieve tension in the classroomslow me down a bit so the students can catch up. He might have to explain the concept two or three different ways, but when he finds an analogy that clicks, it makes teaching really fun. Then students start to understand the more abstract ideas, which makes all the mental exercises worthwhile.

PrithyAdhikary, a senior, has had Aucoin all four years at Caldwell, in classes and labs and as a freshman advisor. She appreciates his humor. He reminds me of Walter White, saidAdhikary, referring to a chemistry teacher in the TV series Breaking Bad. More important, she said, he is the type of professor students can see about day-to-day academic problems, and there will always be a solution.

For Aucoin, connecting with students is a benefit of teaching at a smaller university like Caldwell. In his Principles of Chemistry course for nursing students or in his labs for the general chemistry course or the biochemistry class for junior- and senior-level science students, the atmosphere at Caldwell opens up a world of science that is focused not only on knowledge but also on wisdomhence Caldwells motto ofSapientiaet Scientia, Wisdom and Knowledge. Knowledge is what you know, and wisdom is how you use it, or your application of the knowledge. And they are both important, said Aucoin. That is why you teach classes, but you also show students the practical in the labs.

Biology major Sudeep Khadka has two labs with Aucoin and appreciates that he is open to students ideas. He always says yes to trying projects, said Khadka.

Aucoin and his colleagues in the Department of Natural Sciences encourage student-led research. They have been integrally involved in planning the universitys annual Research and Creative Arts Day and in helping students prepare for the Independent College Fund of New Jerseys annual Research Symposium at which their work is showcased for statewide business and community leaders.

Aucoin sees how research provides many benefits for students beyond the science; they learn professional skills like adaption, trouble-shooting, coming up with new solutions, not getting too frustrated, problem-solving and especially teamwork. All of my lab courses have students working in pairs, he said. Students learn how to collaborate. They divide responsibilities, assist each other with data collection and bond and get to know each other better. This lets them make a friend in the department, which he points out is especially good for his freshmen.

Aucoin remembers what it was like when he was young and discovering the world of science research in Greenville and Smithfield, Rhode Island. His chemistry and physics teachers at Smithfield High School challenged and encouraged him to pursue science studies in college. Then his freshman chemistry teacher at Clark University in Worcester, Massachusetts, sparked his interest in becoming a university professor. He also wore a suit every single day, which is where I got that from, said Aucoin.

He majored in chemistry and biochemistry at Clark and had multiple opportunities to engage in research. I want to make sure we give that opportunity to our students. He went on to graduate school at the State University of New York at Stony Brook, earning a Ph.D. in structural biology; he did his postdoctoral work at Ohio State University where he focused on nuclear magnetic resonanceresearch, examining the proteins associated with diseases like Alzheimers and diabetes. Working with another professor, helearned the ropes of teaching by helping train students, setting up labs and working as a teaching assistant.

Aucoin is aware that many of his 80-plus undergraduate students will enter professions that help others, becoming nurses, doctors, physician assistants or drug designers, and he hopes he can inspire them to ask questions like How can we stop certain diseases from progressing as bad as they get? Can we understand those diseases so we can make better drugs to help people? He believes these are important questions for students to ask themselves, especially at a Catholic Dominican school that is focused on how to serve the common good and to search for and discover the truth.

For Aucoin, a whole world of discovery is waiting to be explored. He and his wife, Hilary, enjoy the great outdoors, hiking up mountainseverywhere from Colorado to New Jersey, where they can find less-traveled places, nice little ponds or lakes and ruins like the Van Slyke Castle in Ramapo. An avid photographer, he always packs a cameraanywhere we go to pick something that has some kind of mountain view or a lake. He and Hilary, along with Natural Sciences Professor AgnesBerki, have taken university students hiking to show them the splendor of the fall foliage. As international students, Khadka andAdhikaryare grateful to discover the beauty of nature in New Jersey and to find that professors are generous with their time. They are like family, saidAdhikary.

Aucoin gives back to the community, volunteering with the middle school and high school Boy Scout troop at St. Aloysius Church in Caldwell, New Jersey. He is happy to be a part of an experienced team that teaches young people how to camp outside in all types of environments, giving them survival skills and confidence in their abilities, he said. As a kid, Aucoin camped outside in all weather conditions, even when it was only 20 degrees and I still have my fingers and toes to prove it.

The skills he learned in scoutinglike leadership, character development, citizen training, and teamworkhave proved to be a good foundation for many aspects of life including his schooling and professional work.

Aucoin especially appreciates the teamwork he sees modeled across campus, and this makes his job worthwhile. Everyone pays so much attention totheir students.The members of his department have good camaraderie. We all get along really well and we help develop ideas together and share resources, he said.

View original post here:
Faculty Feature: Darryl Aucoin: A SCIENCE PROFESSOR'S FORMULA FOR SUCCESS: TEAMWORK, HUMOR AND THE GREAT OUTDOORS - Caldwell University News

Global Itaconic Acid Market is expected to offer significant growth during 2020-2026 | Leading Players : Kehai Biochemistry, Guoguang Biochemistry,…

The Itaconic Acid market report offers an astounding source to analyze the Itaconic Acid Market and other fundamental subtleties recognizing it. The research reveals the comprehensive evaluation and associated views of the Itaconic Acid market. The report presents a feasible synopsis of the Itaconic Acid market, that connects industry chain structure, definitions, applications, and proposals. Moreover, the analysis emphasizes the leading driving industry players (Kehai Biochemistry, Guoguang Biochemistry, Huaming Biochemistry, Alpha Chemika, Zhongshun Science & Technology) all over the globe with company profiles, data of the extensive industry, product type, environment, and demands of a business.

Furthermore, it equates the comprehensive ability of the Itaconic Acid market and arrangements to a fundamental accuracy, expertise, and industry-substantiated evaluations of the worldwide Itaconic Acid market.

Ask for Sample Copy of Report Here: https://www.syndicatemarketresearch.com/market-analysis/itaconic-acid-market.html#sample

The Itaconic Acid market report further concentrates on the top industry manufacturers and examines all essentials aspects of the competitive landscape. It describes consumption capacity, regulatory policies, potential investment opportunities, current actions taken by competitors, as well as market threats and effective business methods and strategies also. The report emphasis essential financial aspects of major manufacturers including production cost analysis, value chain structure, yearly sale, revenue growth, and CAGR.

The report represented Itaconic Acid Industry chain view, raw material cost, labor cost, manufacturing base, and downstream buyers analysis. Also, the import-export statistics, gross margin analysis, and consumption ratio are described. The SWOT analysis and market status for various regions and countries are profiled in the report. The market share and production by product type and application/end-use from 2020-2026are exhibited in this analysis.

Based on Product Type and Application, the Global Itaconic Acid Market mainly divided into:

Geographically, the Itaconic Acid market report examines the major regions and countries, highlighting the productivity, consumption, market size, status and opportunity in those particular regions. Below are the regions covered in the Itaconic Acid report along with their scope of productivity.

Moreover, the report renders the core knowledge of the market by examining the end users consumption habits, Itaconic Acid market driving factors, regularly changing market dynamics, and growing development trends in the market.

Inquiry for Buying Report: https://www.syndicatemarketresearch.com/inquiry/itaconic-acid-market

Additionally, the report presents comprehensive research considering the key contender's market share, size, sales, production capacity, distribution channels, product specification, and cost structure. It is advised to stay always aware of the data and facts regarding this market due to the changes in world business policies.

The research objectives of this report are:

1) To comprehend the structure of the Itaconic Acid market by recognizing its different sub-segments.2) The current progress in the industry, competitive landscape structure, market size evaluation, are explained.3) To receive accurate information about the key factors affecting the market growth (drivers, growth potential, opportunities, specific industry risks, and challenges).4) The pricing structure covering the raw material cost, capacity, demand & supply statistics, and labor cost is presented.5) The market dynamics, competition, and complete insights will begin to valuable business strategies.6) The Itaconic Acid development factors, opportunities, and marketing strategies are explained.

The key dynamic factors that are specified in the report:

Key Market Dynamics: The Global Itaconic Acid Market research report features the most advanced industry trends, research methodologies, and growth methods. The factors that straightly contribute to the growth of the market contain the development platforms, production strategies, and methodologies, and the product type itself, whereas a little change, would result in further changes in the overall report. All of those factors are described in detail in the study report.

Market Outlook: The report also scatters light on some of the major factors, including new product launches, joint ventures, agreements, partnerships, collaborations, R&D, M&A, and growth of the key industry player on global as well as regional basis.

Main Features: The report presents an accurate analysis of some of the important factors, which include capacity, capacity utilization rate, cost, revenue, production, production rate, consumption, supply & demand, import/export, gross margin, market share, and CAGR. Furthermore, the report furnishes a thorough study of the crucial affecting factors and market capabilities, in addition to the relevant market segments and sub-segments.

Analytical Tools: The Global Itaconic Acid Market report made up of the accurately studied and assessed information of the key players and their market scope using various analytical tools, including Porters five forces analysis, investment return analysis, SWOT analysis, and feasibility study. These tools have been utilized to skillfully study the growth of major industry contenders.

Potential Customers: The report provides detailed insights to users, manufacturers, stockholders, service providers, suppliers, and individuals who are interested in evaluating and self-studying this market.

To read full information with TOC on this please visit: https://www.syndicatemarketresearch.com/market-analysis/itaconic-acid-market.html

Lastly, the report assists a reader to get a comprehensive knowledge of the Itaconic Acid industry by details about the industry environment, market projection, growth constraining factors, competitive scenario, entry barriers, limitations, the provincial regulatory framework as well as upcoming market investment, opportunities, and challenges.

This report will render you a clear view of all aspects of the market without a requirement to refer to any extra research report or a data source. Our report will offer you every fact about the past, present, and future of the concerned market.

Sorry! The Author has not filled his profile.

See original here:
Global Itaconic Acid Market is expected to offer significant growth during 2020-2026 | Leading Players : Kehai Biochemistry, Guoguang Biochemistry,...

Trending (2020-2026): Carvacrol Market is Booming Worldwide with Top Growing Companies | Foreverest Resources Ltd, Weifang Union Biochemistry – Keep…

Global Carvacrol Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Los Angeles, United State,20February 2020 The report titled Global Carvacrol Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Carvacrol market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Carvacrol market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Carvacrol market is carefully analyzed and researched about by the market analysts.

>>>Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart):https://www.qyresearch.com/sample-form/form/928385/global-carvacrol-industry-chain-research-report-2019

The Essential Content Covered in the Global Carvacrol Market Report:Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Top Key Players of the Global Carvacrol Market:SHUBH Flavour And Fragrances Pvt., Foreverest Resources Ltd, Weifang Union Biochemistry, Anhui Haibei Import & Export Co., Hairui Natural Plant Co., High Hope Intl Group, Jiangxi Baicao Pharmaceutical, Shree Bankey Behari Lal Aromatics, Fuzhou Farwell Import & Export Co., Kunshan Sainty Y.J.Y. Co., Xian Aladdin Biological Technology

Global Carvacrol Market Segmentation By Product:Natural Type, Synthetic Type

Global Carvacrol Market Segmentation By Application:Flavors and Fragrances, Food Additives, Pharmaceutical Intermediates, Other

In terms of region, this research report covers almost all the major regions across the globe such asNorth America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Carvacrol Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Carvacrol Market in South, America region is also expected to grow in near future.

Key questions answered in the report*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Carvacrol market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

Why to Buy this Report?

>>>Request Customization of Report :https://www.qyresearch.com/customize-request/form/928385/global-carvacrol-industry-chain-research-report-2019

Table of Contents

Executive Summary1 Carvacrol Market Overview1.1 Product Overview and Scope of Carvacrol1.2 Carvacrol Segment by Type1.2.1 Global Carvacrol Production Growth Rate Comparison by Type (2014-2025)1.2.2 Natural Type1.2.3 Synthetic Type1.3 Carvacrol Segment by Application1.3.1 Carvacrol Consumption Comparison by Application (2014-2025)1.3.2 Flavors and Fragrances1.3.3 Food Additives1.3.4 Pharmaceutical Intermediates1.3.5 Other1.3 Global Carvacrol Market by Region1.3.1 Global Carvacrol Market Size Region1.3.2 North America Status and Prospect (2014-2025)1.3.3 Europe Status and Prospect (2014-2025)1.3.4 China Status and Prospect (2014-2025)1.3.5 Japan Status and Prospect (2014-2025)1.3.6 Southeast Asia Status and Prospect (2014-2025)1.3.7 India Status and Prospect (2014-2025)1.4 Global Carvacrol Market Size1.4.1 Global Carvacrol Revenue (2014-2025)1.4.2 Global Carvacrol Production (2014-2025)

2 Global Carvacrol Market Competition by Manufacturers2.1 Global Carvacrol Production Market Share by Manufacturers (2014-2019)2.2 Global Carvacrol Revenue Share by Manufacturers (2014-2019)2.3 Global Carvacrol Average Price by Manufacturers (2014-2019)2.4 Manufacturers Carvacrol Production Sites, Area Served, Product Types2.5 Carvacrol Market Competitive Situation and Trends2.5.1 Carvacrol Market Concentration Rate2.5.2 Carvacrol Market Share of Top 3 and Top 5 Manufacturers2.5.3 Mergers & Acquisitions, Expansion

3 Global Carvacrol Production Market Share by Regions3.1 Global Carvacrol Production Market Share by Regions3.2 Global Carvacrol Revenue Market Share by Regions (2014-2019)3.3 Global Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)3.4 North America Carvacrol Production3.4.1 North America Carvacrol Production Growth Rate (2014-2019)3.4.2 North America Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)3.5 Europe Carvacrol Production3.5.1 Europe Carvacrol Production Growth Rate (2014-2019)3.5.2 Europe Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)3.6 China Carvacrol Production (2014-2019)3.6.1 China Carvacrol Production Growth Rate (2014-2019)3.6.2 China Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)3.7 Japan Carvacrol Production (2014-2019)3.7.1 Japan Carvacrol Production Growth Rate (2014-2019)3.7.2 Japan Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Carvacrol Consumption by Regions4.1 Global Carvacrol Consumption by Regions4.2 North America Carvacrol Consumption (2014-2019)4.3 Europe Carvacrol Consumption (2014-2019)4.4 China Carvacrol Consumption (2014-2019)4.5 Japan Carvacrol Consumption (2014-2019)

5 Global Carvacrol Production, Revenue, Price Trend by Type5.1 Global Carvacrol Production Market Share by Type (2014-2019)5.2 Global Carvacrol Revenue Market Share by Type (2014-2019)5.3 Global Carvacrol Price by Type (2014-2019)5.4 Global Carvacrol Production Growth by Type (2014-2019)

6 Global Carvacrol Market Analysis by Applications6.1 Global Carvacrol Consumption Market Share by Application (2014-2019)6.2 Global Carvacrol Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Carvacrol Business7.1 SHUBH Flavour And Fragrances Pvt.7.1.1 SHUBH Flavour And Fragrances Pvt. Carvacrol Production Sites and Area Served7.1.2 Carvacrol Product Introduction, Application and Specification7.1.3 SHUBH Flavour And Fragrances Pvt. Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.1.4 Main Business and Markets Served7.2 Foreverest Resources Ltd7.2.1 Foreverest Resources Ltd Carvacrol Production Sites and Area Served7.2.2 Carvacrol Product Introduction, Application and Specification7.2.3 Foreverest Resources Ltd Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.2.4 Main Business and Markets Served7.3 Weifang Union Biochemistry7.3.1 Weifang Union Biochemistry Carvacrol Production Sites and Area Served7.3.2 Carvacrol Product Introduction, Application and Specification7.3.3 Weifang Union Biochemistry Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.3.4 Main Business and Markets Served7.4 Anhui Haibei Import & Export Co.7.4.1 Anhui Haibei Import & Export Co. Carvacrol Production Sites and Area Served7.4.2 Carvacrol Product Introduction, Application and Specification7.4.3 Anhui Haibei Import & Export Co. Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.4.4 Main Business and Markets Served7.5 Hairui Natural Plant Co.7.5.1 Hairui Natural Plant Co. Carvacrol Production Sites and Area Served7.5.2 Carvacrol Product Introduction, Application and Specification7.5.3 Hairui Natural Plant Co. Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.5.4 Main Business and Markets Served7.6 High Hope Intl Group7.6.1 High Hope Intl Group Carvacrol Production Sites and Area Served7.6.2 Carvacrol Product Introduction, Application and Specification7.6.3 High Hope Intl Group Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.6.4 Main Business and Markets Served7.7 Jiangxi Baicao Pharmaceutical7.7.1 Jiangxi Baicao Pharmaceutical Carvacrol Production Sites and Area Served7.7.2 Carvacrol Product Introduction, Application and Specification7.7.3 Jiangxi Baicao Pharmaceutical Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.7.4 Main Business and Markets Served7.8 Shree Bankey Behari Lal Aromatics7.8.1 Shree Bankey Behari Lal Aromatics Carvacrol Production Sites and Area Served7.8.2 Carvacrol Product Introduction, Application and Specification7.8.3 Shree Bankey Behari Lal Aromatics Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.8.4 Main Business and Markets Served7.9 Fuzhou Farwell Import & Export Co.7.9.1 Fuzhou Farwell Import & Export Co. Carvacrol Production Sites and Area Served7.9.2 Carvacrol Product Introduction, Application and Specification7.9.3 Fuzhou Farwell Import & Export Co. Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.9.4 Main Business and Markets Served7.10 Kunshan Sainty Y.J.Y. Co.7.10.1 Kunshan Sainty Y.J.Y. Co. Carvacrol Production Sites and Area Served7.10.2 Carvacrol Product Introduction, Application and Specification7.10.3 Kunshan Sainty Y.J.Y. Co. Carvacrol Production, Revenue, Price and Gross Margin (2014-2019)7.10.4 Main Business and Markets Served7.11 Xian Aladdin Biological Technology

8 Carvacrol Manufacturing Cost Analysis8.1 Carvacrol Key Raw Materials Analysis8.1.1 Key Raw Materials8.1.2 Price Trend of Key Raw Materials8.1.3 Key Suppliers of Raw Materials8.2 Proportion of Manufacturing Cost Structure8.3 Manufacturing Process Analysis of Carvacrol8.4 Carvacrol Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers9.1 Marketing Channel9.1.1 Direct Marketing9.1.2 Indirect Marketing9.2 Carvacrol Distributors List9.3 Carvacrol Customers

10 Market Dynamics10.1 Market Trends10.2 Opportunities10.3 Market Drivers10.4 Challenges10.5 Influence Factors

11 Global Carvacrol Market Forecast11.1 Global Carvacrol Production, Revenue Forecast11.1.1 Global Carvacrol Production Growth Rate Forecast (2019-2025)11.1.2 Global Carvacrol Revenue and Growth Rate Forecast (2019-2025)11.1.3 Global Carvacrol Price and Trend Forecast (2019-2025)11.2 Global Carvacrol Production Forecast by Regions (2019-2025)11.2.1 North America Carvacrol Production, Revenue Forecast (2019-2025)11.2.2 Europe Carvacrol Production, Revenue Forecast (2019-2025)11.2.3 China Carvacrol Production, Revenue Forecast (2019-2025)11.2.4 Japan Carvacrol Production, Revenue Forecast (2019-2025)11.3 Global Carvacrol Consumption Forecast by Regions (2019-2025)11.3.1 North America Carvacrol Consumption Forecast (2019-2025)11.3.2 Europe Carvacrol Consumption Forecast (2019-2025)11.3.3 China Carvacrol Consumption Forecast (2019-2025)11.3.4 Japan Carvacrol Consumption Forecast (2019-2025)11.4 Global Carvacrol Production, Revenue and Price Forecast by Type (2019-2025)11.5 Global Carvacrol Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original here:
Trending (2020-2026): Carvacrol Market is Booming Worldwide with Top Growing Companies | Foreverest Resources Ltd, Weifang Union Biochemistry - Keep...